Aktien Sensor

Novartis AG has made significant progress in research and development, with a Phase III study for its treatment candidate ianalumab showing promising results in treating primary immune thrombocytopenia (ITP).

Novartis AG’s breakthrough drug candidate, Ianalumab, has exceeded expectations in clinical trials for ITP and Sjögren’s disease, leading to a significant increase in stock price and solidifying the company’s position as a leader in medical researc…

Novartis’ stock price sees a modest increase amid rumors of potential takeover talks with US biotech firm Avidity Biosciences.

Novartis is facing a significant challenge from US trade policies, but sees an opportunity to capitalize on the growing interstitial cystitis market.

Novartis receives FDA approval for its medication Leqvio, but its stock price is impacted by US President Trump’s demands for lower medication prices.

Novartis reports record sales for its medication Kisqali in the second quarter, despite global market uncertainty surrounding the US-China trade agreement.

Novartis AG’s stock price has declined, but the company’s innovative treatments and robust succession plan ensure its position as a leader in the pharmaceutical industry.

Novartis has secured regulatory approval for Coartem Baby, a groundbreaking malaria treatment specifically designed for newborn babies and young infants.

Novartis AG’s key medication, Cosentyx, has failed to meet its primary endpoint in a Phase III study, leading to a decline in sales expectations and potential financial impact on the company.

Novartis’ flagship medication Cosentyx has failed to meet its primary endpoint in a Phase III study, dealing a significant blow to the company’s revenue hopes and stock price.